1. Home
  2. ENTG vs UTHR Comparison

ENTG vs UTHR Comparison

Compare ENTG & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Entegris Inc.

ENTG

Entegris Inc.

HOLD

Current Price

$127.83

Market Cap

21.1B

Sector

Industrials

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$546.33

Market Cap

25.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTG
UTHR
Founded
1966
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Plastic Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.1B
25.1B
IPO Year
2000
1999

Fundamental Metrics

Financial Performance
Metric
ENTG
UTHR
Price
$127.83
$546.33
Analyst Decision
Buy
Buy
Analyst Count
10
14
Target Price
$133.67
$567.57
AVG Volume (30 Days)
2.5M
387.4K
Earning Date
04-30-2026
05-06-2026
Dividend Yield
0.27%
N/A
EPS Growth
N/A
13.07
EPS
0.60
5.82
Revenue
$3,196,600,000.00
$1,483,300,000.00
Revenue This Year
$9.27
$6.39
Revenue Next Year
$9.50
$14.18
P/E Ratio
$232.77
$94.18
Revenue Growth
N/A
2.38
52 Week Low
$67.97
$272.18
52 Week High
$159.15
$609.35

Technical Indicators

Market Signals
Indicator
ENTG
UTHR
Relative Strength Index (RSI) 40.24 40.52
Support Level $122.00 $464.92
Resistance Level $140.75 $608.62
Average True Range (ATR) 7.49 12.82
MACD -0.56 -2.97
Stochastic Oscillator 17.75 23.73

Price Performance

Historical Comparison
ENTG
UTHR

About ENTG Entegris Inc.

Entegris is a leading supplier of purification solutions and advanced materials. The vast majority of sales are to the semiconductor industry. The majority of revenue comes from semiconductor fabricators, but the company sells to all areas of the semiconductor manufacturing supply chain including equipment and engineering, chemicals and materials, and distributors. Entegris specializes in materials science and materials purity, both of which are crucial in the semiconductor manufacturing process.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: